AccurKardia Wins Patent for AI-Driven ECG Detection of Cardiac Amyloidosis

AccurKardia revealed it’s been granted U.S. Patent No. 12,620,488 for its proprietary machine learning-based system to identify cardiac amyloidosis from a standard, routinely performed 12-lead ECG.

Cardiac amyloidosis occurs when abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and eventually fail. The condition is widely underdiagnosed—most patients are identified only after permanent heart damage has already happened.

Catching it sooner moves patient away from standard heart failure treaments that can be ineffective or even harmful, and toward therapies that are proven to improve survival.

“Cardiac amyloidosis hides in plain sight, and because the symptoms are quite similar to other causes of heart failure, we have historically relied on expensive, late-stage imaging to diagnose what is already advanced disease, often after conventional medical therapy has failed to improve symptoms,” said Dr. Jason Lazar, executive vice dean, chair of the Department of Medical Education and Director of Non-invasive Cardiology at SUNY Downstate. “A reliable ECG-based screening signal, leveraging information the human eye simply cannot extract, has the potential to redefine when and how we intervene, particularly as therapeutic options continue to expand. Simply put, earlier diagnosis leads to much better outcomes.”

AccurKardia’s patent establishes its IP foundation for all major amyloidosis subtypes, including AL amyloidosis and wild-type and hereditary ATTR amyloidosis. It joins the company’s pipeline of AI-ECG biomarkers that includes Breakthrough Device-designated algorithms for aortic stenosis (AK-AVS) and hyperkalemia (AK+ Guard), alongside the company’s FDA-cleared automated ECG interpretation platform, AccurECG 2.0.

“Disease-modifying amyloidosis therapies are among the most important advances in cardiology in a generation, but their impact is gated by our ability to find the right patients in time,” said Juan C. Jimenez, co-founder and CEO of AccurKardia. “This patent establishes the foundation for closing that gap. We are turning a test that is already performed millions of times per year globally into a screening biomarker, deployable without new hardware or procedures, seamlessly integrating our capabilities into existing workflows.”